"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Pembrolizumab (Keytruda) plus Axitinib for Advanced RCC

22 Apr 2019 1:39 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software